Literature DB >> 8248659

Applying Bayesian ideas in drug development and clinical trials.

D J Spiegelhalter1, L S Freedman, M K Parmar.   

Abstract

The Bayesian paradigm emphasizes that studies are not performed in isolation, and that external evidence can be used formally in the design, monitoring and reporting of clinical trials. A variety of tools for assessing the current evidence for treatment efficacy are presented, making use of graphical display to provide insight into ethical and efficiency issues in starting and stopping trials--these are illustrated with a trial in osteosarcoma that is currently taking place. Finally we recommend that an additional 'interpretation' section is placed in clinical reports to provide a bridge between 'results' and 'discussion'--it is this section that would contain the Bayesian perspective.

Entities:  

Mesh:

Year:  1993        PMID: 8248659     DOI: 10.1002/sim.4780121516

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

1.  CORR Insights®: Prediction of Postoperative Clinical Recovery of Drop Foot Attributable to Lumbar Degenerative Diseases, via a Bayesian Network.

Authors:  Raphaël Porcher
Journal:  Clin Orthop Relat Res       Date:  2017-01-03       Impact factor: 4.176

2.  A Bayesian approach to Weibull survival models--application to a cancer clinical trial.

Authors:  K Abrams; D Ashby; D Errington
Journal:  Lifetime Data Anal       Date:  1996       Impact factor: 1.588

3.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

Review 4.  Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study.

Authors:  Laura Bojke; Marta Soares; Karl Claxton; Abigail Colson; Aimée Fox; Christopher Jackson; Dina Jankovic; Alec Morton; Linda Sharples; Andrea Taylor
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

5.  Evaluation of a predevelopment service delivery intervention: an application to improve clinical handovers.

Authors:  Guiqing Lily Yao; Nicola Novielli; Semira Manaseki-Holland; Yen-Fu Chen; Marcel van der Klink; Paul Barach; Peter J Chilton; Richard J Lilford
Journal:  BMJ Qual Saf       Date:  2012-09-13       Impact factor: 7.035

Review 6.  Sample size: how many patients are necessary?

Authors:  P M Fayers; D Machin
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

7.  Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Authors:  Bas C Stunnenberg; Willem Woertman; Joost Raaphorst; Jeffrey M Statland; Robert C Griggs; Janneke Timmermans; Christiaan G Saris; Bas J Schouwenberg; Hans M Groenewoud; Dick F Stegeman; Baziel G M van Engelen; Gea Drost; Gert Jan van der Wilt
Journal:  BMC Neurol       Date:  2015-03-25       Impact factor: 2.474

8.  A Quantitative Process for Enhancing End of Phase 2 Decisions.

Authors:  Tony Sabin; James Matcham; Sarah Bray; Andrew Copas; Mahesh K B Parmar
Journal:  Stat Biopharm Res       Date:  2014-02-01       Impact factor: 1.452

9.  Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy.

Authors:  Alberto Carmona-Bayonas; Caterina Calderón; Raquel Hernández; Ana Fernández Montes; Beatriz Castelo; Laura Ciria-Suarez; Mónica Antoñanzas; Jacobo Rogado; Vilma Pacheco-Barcia; Elena Asensio Martínez; Alejandra Ivars; Francisco Ayala de la Peña; Paula Jimenez-Fonseca
Journal:  NPJ Breast Cancer       Date:  2021-07-13

10.  Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).

Authors:  N Katsumata; H Yoshikawa; H Kobayashi; T Saito; K Kuzuya; T Nakanishi; T Yasugi; N Yaegashi; H Yokota; S Kodama; T Mizunoe; M Hiura; T Kasamatsu; T Shibata; T Kamura
Journal:  Br J Cancer       Date:  2013-05-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.